Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

Contact Us

Search

SCLC

Onco_background

Oncology Weekly News - August 18th 2025

🔬🧬 Oncology Updates: Keytruda Approval, Nanobody Breakthrough, Radioligand Deal…

Onco_background

Oncology Weekly News - June 9th 2025

🔬🧬 Oncology Updates: IMDELLTRA Breakthroughs, Breast Cancer Advances, and…

Cell_Gene_Therapy

Cell and Gene Therapy Weekly News - June 5th 2025

This Week in Gene & Cell Therapy: Breakthrough Trials, Fast Track…

Onco_background

Oncology Weekly News - May 26th 2025

🧬🚀Oncology Update: Breakthrough Trials, Drug Approvals & New Therapies.…

ELCC 2025_Preview_by_LucidQuest

ELCC 2025 Preview: Key Lung Cancer Highlights to Watch

ELCC 2025 at a glance Looking toward ELCC 2025, LucidQuest highlights…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates
Lucid Diligence Brief: Insilico-TaiGen CKD anemia licensing deal
Lucid Diligence Brief: Pfizer YaoPharma oral GLP-1 deal
Vaccines Video Recap—December 12, 2025
Vaccines Today—December 12, 2025

Tags

AAAAI 2025 Abeona advanced therapies american college of cardiology Anti-Vaccine Movement Asundexian Atogepant BIA bioinformatics brain tumors cancer Celea Therapeutics ckd climate change and health Clinical immunology Congenital aceruloplasminemia corporate venture capital drug pricing drug supply chain Elismetrep Elranatamab ESMO 2021 facial rejuvenation gene editing gene therapy approval gi oncology Helicobacter pylori hematology investment managed entry agreements nanotechnology NFTs in healthcare NIHR Southampton non viral vectors oncology trials peptibody mRNA therapy Perioperative immunotherapy pharma radiation oncology Recurrent respiratory papillomatosis remote patient monitoring Sema4 SKYRIZI tissue engineering unconventional trial designs

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates
Lucid Diligence Brief: Insilico-TaiGen CKD anemia licensing deal
Lucid Diligence Brief: Pfizer YaoPharma oral GLP-1 deal
Vaccines Video Recap—December 12, 2025
Vaccines Today—December 12, 2025

TAGS

AAAAI 2025 Abeona advanced therapies american college of cardiology Anti-Vaccine Movement Asundexian Atogepant BIA bioinformatics brain tumors cancer Celea Therapeutics ckd climate change and health Clinical immunology Congenital aceruloplasminemia corporate venture capital drug pricing drug supply chain Elismetrep Elranatamab ESMO 2021 facial rejuvenation gene editing gene therapy approval gi oncology Helicobacter pylori hematology investment managed entry agreements nanotechnology NFTs in healthcare NIHR Southampton non viral vectors oncology trials peptibody mRNA therapy Perioperative immunotherapy pharma radiation oncology Recurrent respiratory papillomatosis remote patient monitoring Sema4 SKYRIZI tissue engineering unconventional trial designs

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy